busulfex

DRUG2 trials

Sponsors

Dana-Farber Cancer Institute

Conditions

GVHDGraft Versus Host DiseaseHemoglobinopathiesSickle Cell DiseaseThalassemia

Phase 2

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

CompletedNCT00153985

Dana-Farber Cancer InstituteHemoglobinopathies, Sickle Cell Disease, Thalassemia

Start: 2004-03-31End: 2009-07-31Updated: 2013-07-30

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

CompletedNCT00282282

Dana-Farber Cancer InstituteGraft Versus Host Disease, GVHD

Start: 2006-01-31End: 2009-07-31Updated: 2014-05-12